Regeneron Pharmaceuticals, Inc.
- Last sale
- Oct 30, 2026 · +13.52%
- Market cap
- $95.96B
- 103.45M shares
- Filings
- 1,070
Q3 2026+1.0% FY25 yoy
Q3 2026+2.1% FY25 yoy
Q3 2026−10.3% FY25 yoy
Q3 2026derived+11.3% FY25 yoy
Q3 2026+8.2% FY25 yoy
Q3 2026+25.3% FY25 yoy
- $95.96B
- 19.9×
- 5.7×
- 2.9×
- 3.99%
- 0.40%
Twelve months to Sep 30, 2026 · derived
Price
Oct 30, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $14,342,900,000 | reported | |
| FY 2024 | 2024-12-31 | $14,202,000,000 | reported | |
| FY 2023 | 2023-12-31 | $13,117,200,000 | reported | |
| FY 2022 | 2022-12-31 | $12,172,900,000 | reported | |
| FY 2021 | 2021-12-31 | $16,071,700,000 | reported | |
| FY 2020 | 2020-12-31 | $8,497,100,000 | reported | |
| FY 2019 | 2019-12-31 | $6,557,600,000 revised | reported | |
| FY 2018 | 2018-12-31 | $5,145,600,000 revised | reported | |
| FY 2017 | 2017-12-31 | $5,872,200,000 | reported | |
| FY 2016 | 2016-12-31 | $4,860,400,000 | reported | |
| FY 2015 | 2015-12-31 | $4,103,728,000 | reported | |
| FY 2014 | 2014-12-31 | $2,819,557,000 | reported |
Capital returns
| Fiscal year | Dividends | Buybacks | Total | Per share | Shares | Shares · yoy | of free cash flow |
|---|---|---|---|---|---|---|---|
| FY2025 | $370.30M | $3.44B | $3.81B | — | — | — | 93.3% |
| FY2024 | $0.00 | $2.60B | $2.60B | — | — | — | 71.0% |
| FY2023 | $0.00 | $2.24B | $2.24B | — | — | — | 57.7% |
| FY2022 | — | $2.08B | $2.08B | — | — | — | 47.1% |
| FY2021 | — | $1.65B | $1.65B | — | — | — | 25.2% |
Segments
Products
LineFY2025ShareChange
Collaboration revenue$7.33B51%+21.0%
Net product sales$6.31B44%−17.3%
Libtayo$1.45B10%+19.3%
Other revenue$702.60M4.9%+36.4%
Other products$10.10M0.1%—
Sanofi collaboration revenue———
Total$14.34B
Pharmaceutical preparations
Regeneron Pharmaceuticals, Inc. is the 11th largest of the 554 covered companies the SEC files under this code, by revenue. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
UPCUniverse Pharmaceuticals INC$17.9B22.4%20.6%—TEVATeva Pharmaceutical Industries Ltd$17.3B4.3%8.2%$50.9B
REGNRegeneron Pharmaceuticals, Inc. (this company)$14.3B1.0%31.4%$96.0B
VTRSViatris Inc$14.3B3.0%24.6%$23.7BVRTXVertex Pharmaceuticals Inc$12.0B8.9%32.9%$137.6BBHCBausch Health Companies Inc.$10.3B6.7%1.5%$3.1BZTSZoetis Inc.$9.5B2.3%28.2%$33.7BOGNOrganon & Co.$6.2B2.9%3.0%$3.7BONCBeOne Medicines Ltd.$5.3B40.2%5.4%$617.8BPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Regeneron Pharmaceuticals, Inc. · CIK 872589 · Engraved from SEC EDGAR